SLC5A2 and atrial fibrillation: We hypothesized that reduced AF rates associated with SGLT2 inhibitor use are in part due to previously unrecognized antiarrhythmic electrophysiological effects of dapagliflozin that are achieved by direct drug effects on atrial repolarizing potassium channels.